Compare Cytokinetics Inc (CYTK) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Wolfspeed Inc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Wolfspeed Inc trades at $35.45 (market cap $1.78B). The key difference: Cytokinetics Inc is far larger — about 6.2× Wolfspeed Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | WOLF | |
|---|---|---|
Market Cap | $11.12B | $1.78B |
Sector | Technology | Technology |
52-Week High | $87.26 | $73.68 |
52-Week Low | $33.23 | $1.19 |
Enterprise Value | $11.59B | $2.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Wolfspeed (WOLF) trades at $33.65, down 4.65% today amid bearish technical signals and negative profitability metrics. The stock shows mixed earnings performance with recent beats but a significant Q4 2025 miss. Recent developments include a patent lawsuit against Navitas Semiconductor and strategic partnerships with GE Aerospace, positioning the company in high-growth AI and defense markets despite current financial challenges.
The outlook remains cautious with analyst consensus leaning neutral (47.37% Hold). While strategic pivots to data centers and defense offer growth potential, negative margins and bearish technicals present near-term risks. Investors should monitor earnings improvement and market share gains in silicon carbide technology for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
